Empasiprubart IV Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 29, 2026

The clinical evidence base for Empasiprubart IV comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including . Most recent publication: The changing landscape of primary autoimmune neuropathies., Nat Rev Neurol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

The changing landscape of primary autoimmune neuropathies.
Caballero-Ávila M, Pascual-Goñi E, Lleixà C, et al. · Nat Rev Neurol · 2025
PubMed: PMID 40913126 · NCT06742190 (Empassion)

Publications by year

2025–2025: 1 publications.

2025

Publications by journal

Nat Rev Neurol1 paper

All Empasiprubart IV publications (1)

2025 (1 paper)

The changing landscape of primary autoimmune neuropathies.
Caballero-Ávila M, Pascual-Goñi E, Lleixà C, et al. · Nat Rev Neurol · 2025 · Derived
PubMed: PMID 40913126 · NCT06742190 (Empassion)

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Fri, 29 May 2026 17:33:28 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).